查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2044653

胰島素生物相似藥市場：市場洞察、競爭格局及市場預測（2033 年）

Insulin Biosimilars Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 199 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

隨著醫療保健系統將經濟實惠的糖尿病治療、提高胰島素可及性以及永續的慢性病管理列為優先事項，全球胰島素生物相似藥市場正邁入更強勁的成長階段。 2026年，該市場規模為63億美元，預計2033年將達到102億美元，預測期內複合年成長率（CAGR）為7.10%。胰島素生物相似藥作為一種切實可行的替代方案，正日益受到關注，它們在品質、安全性和療效方面與原廠胰島素產品相當，同時也有助於降低治療成本。隨著已開發市場和新興市場糖尿病患者數量的不斷增加，對可靠且經濟有效的胰島素製劑的需求預計將持續成長。

市場洞察

隨著患者、醫療服務提供者、保險公司和政府尋求兼顧臨床療效和可負擔性的治療方法，胰島素生物相似藥在糖尿病治療系統中佔了越來越重要的地位。此市場涵蓋用於治療第1型和第2型糖尿病的速效、中效和長效胰島素產品。人們對生物相似藥的信心不斷增強、法規結構的不斷改進以及醫生認知度的提高，都在推動其應用。隨著更多胰島素生物相似藥進入市場，預計競爭將有助於提高供應穩定性和價格柔軟性。

此外，生物製藥的生產製造、分析檢測和品管方面的進步也促進了該市場的發展。這些進步使生產商更容易證明其產品與參考產品的等效性，並建立醫療專業人員的信任。醫院藥局、零售藥局、藥局和網路藥局在擴大病患用藥管道方面發揮著至關重要的作用。特別是對於需要定期續購處方箋的患者而言，網路藥局的重要性日益凸顯，因為數位化醫療平台使得慢性病藥物的取得更加便捷。

成長要素

糖尿病盛行率的不斷上升持續成長要素。肥胖症的增加、久坐的生活方式、人口老化、不健康的飲食以及都市化，都導致全球糖尿病患者人數不斷增加。 1型糖尿病患者依賴胰島素維持生命，許多第二型糖尿病患者隨著病情進展也需要胰島素治療。這使得市場對安全、有效且價格合理的胰島素產品的需求持續成長。

品牌胰島素治療的高成本也加速了人們對生物相似藥的興趣。許多醫療保健系統面臨著在保持醫療品質的同時降低藥物成本的壓力。生物相似胰島素產品有助於患者和支付方節省成本，從而提高用藥依從性並降低治療中斷的風險。現有胰島素產品專利到期也為生物相似藥生產商進入市場創造了更多機會。

此外，有利的監管流程正在推動產品研發和商業化。明確的核准標準、不斷累積的臨床經驗以及臨床醫生日益成長的認可度，都增強了市場前景。隨著生物相似胰島素產品的普及，醫療專業人員有望更有信心將其用於新舊患者的治療。

商業機會

胰島素生物相似藥市場為製藥公司、生物技術公司、契約製造生產商和分銷合作夥伴提供了巨大的機會。能夠以具有競爭力的價格提供高品質胰島素生物相似藥的公司，將佔有利地位，從不斷成長的市場需求中獲益。長效胰島素生物相似藥因其在日常糖尿病管理中的便利性，預計將帶來顯著的市場機會；而速效胰島素類似物則可能在需要餐前血糖控制的患者中越來越受歡迎。

全球製藥公司與區域性生產商之間的合作有助於提高市場滲透率，尤其是在價格敏感型國家。在地化生產、高效的低溫運輸配送和完善的藥局網路對於擴大藥品可及性至關重要。此外，企業還可以透過提供患者支持項目、教育活動以及與胰島素筆和胰島素筆芯等醫療設備相容的胰島素劑型來鞏固其市場地位。

數位醫療平台也帶來了新的機會。利用線上藥局和遠端醫療進行糖尿病護理有助於提高治療的連續性、處方續處方箋管理和病患教育水準。能夠提供價格合理、供應穩定、臨床數據可靠且上市後安全性監測完善的製造商可望獲得競爭優勢。

區域分析

北美是胰島素生物相似藥的關鍵市場，這得益於其高糖尿病盛行率、先進的醫療基礎設施以及對價格合理的胰島素日益成長的需求。保險公司、醫療服務提供者和政策制定者正擴大探索生物相似藥方案，以降低治療成本並提高藥物可近性。監管支持和日益激烈的市場競爭預計將進一步加速該地區的市場滲透。

歐洲也是一個重要的市場，這得益於生物相似藥的廣泛接受度、完善的報銷體係以及醫生對生物製藥製劑的了解。該地區在多個治療領域率先採用了生物相似藥，為胰島素生物相似藥的發展創造了有利環境。

亞太地區糖尿病患者數量眾多，醫療服務覆蓋率不斷擴大，國內生物相似藥產量不斷提高，預計該地區將迎來顯著的成長機會。該地區各國致力於改善慢性病管理，減少對昂貴進口藥品的依賴。在拉丁美洲和中東及非洲，隨著各國政府和醫療機構對價格較親民的胰島素產品的需求，預計生物相似藥的普及也將逐步推進。在所有地區，成長都將取決於監管機構的信心、定價政策、醫生教育以及病人的接受度。

大公司

競爭格局包括成熟的胰島素生產商、全球製藥公司、生物相似藥研發公司以及致力於改善糖尿病治療可近性的區域性公司。胰島素和生物相似藥市場的主要參與者包括：

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi SA
  • Biocon Biologics Ltd.
  • Viatris Inc.
  • Boehringer Ingelheim
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Gan & Lee Pharmaceuticals Co., Ltd.
  • Wockhardt Ltd.
  • Julphar Gulf Pharmaceutical Industries
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Ypsomed AG
  • Lannett Company, Inc.
  • Sandoz Group AG

分割

按類型

  • 速效胰島素、速效胰島素類似物、常規人類胰島素
  • 中效胰島素、NPH人類胰島素、預混合料胰島素
  • 長效胰島素

適應

  • 1型糖尿病
  • 2型糖尿病

按銷售管道

  • 醫院藥房
  • 零售藥房
  • 藥局
  • 網路藥房

按地區

  • 北美洲
  • 拉丁美洲
  • 亞太地區
  • 歐洲
  • 中東和非洲

目錄

第1章：摘要整理

第2章 市場概覽

  • 市場定義與細分
  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機遇
  • 價值鏈分析
  • 新冠疫情影響分析
  • 波特五力分析
  • 俄烏衝突的影響
  • PESTLE分析
  • 監管分析
  • 價格趨勢分析
    • 當前價格及未來預測（2025-2033）
    • 價格影響因素

第3章：2020-2033年全球胰島素生物相似藥市場展望

  • 全球胰島素生物相似藥市場展望：按類型、價值（十億美元）和銷售（單位）分類，2020-2033年
    • 速效胰島素
    • 中效胰島素
    • 長效胰島素
  • 全球胰島素生物相似藥市場展望：按適應症、價值（十億美元）和銷售（單位）分類，2020-2033年
    • 1型糖尿病
    • 2型糖尿病
  • 全球胰島素生物相似藥市場展望：按分銷管道、價值（十億美元）和銷售（單位）分類，2020-2033年
    • 醫院藥房
    • 零售藥房
    • 藥局
    • 網路藥房
  • 全球胰島素生物相似藥市場展望：按地區、價值（十億美元）和銷售分類，2020-2033年
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第4章：2020-2033年北美胰島素生物相似藥市場展望

第5章：2020-2033年歐洲胰島素生物相似藥市場展望

第6章：2020-2033年亞太地區胰島素生物相似藥市場展望

第7章：2020-2033年拉丁美洲胰島素生物相似藥市場展望

第8章：2020-2033年中東和非洲胰島素生物相似藥市場展望

第9章 競爭情勢

  • 公司與細分市場熱圖
  • 2025年各公司市佔率分析
  • 競爭對手儀表板
  • 公司簡介
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Sanofi SA
    • Biocon Biologics Ltd.
    • Viatris Inc.
    • Boehringer Ingelheim
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Gan & Lee Pharmaceuticals Co., Ltd.
    • Wockhardt Ltd.
    • Julphar Gulf Pharmaceutical Industries
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Ypsomed AG
    • Lannett Company, Inc.
    • Sandoz Group AG

第10章附錄

簡介目錄

The global Insulin Biosimilars Market is moving into a stronger growth phase as healthcare systems prioritize affordable diabetes treatment, wider insulin access, and sustainable chronic disease management. The market is valued at US$ 6.3 Bn in 2026 and is projected to reach US$ 10.2 Bn by 2033, growing at a CAGR of 7.10% during the forecast period. Insulin biosimilars are increasingly viewed as practical alternatives to reference insulin products because they offer comparable quality, safety, and effectiveness while helping reduce treatment costs. With diabetes cases rising across both developed and emerging economies, demand for reliable and cost-efficient insulin options is expected to increase steadily.

Market Insights

Insulin biosimilars are becoming an important part of the diabetes care ecosystem as patients, providers, payers, and governments look for therapies that balance clinical performance with affordability. The market includes fast-acting insulin, intermediate-acting insulin, and long-acting insulin products used across Type 1 and Type 2 diabetes treatment. Growing confidence in biosimilar medicines, stronger regulatory frameworks, and increasing physician awareness are supporting broader adoption. As biosimilar insulin products enter more markets, competition is expected to improve availability and pricing flexibility.

The market is also benefiting from improvements in biologics manufacturing, analytical testing, and quality control. These advancements are helping manufacturers demonstrate similarity to reference products and build trust among healthcare professionals. Hospital pharmacies, retail pharmacies, drug stores, and online pharmacies are playing important roles in expanding patient access. Online pharmacies, in particular, are gaining relevance as digital healthcare platforms make chronic disease medicines easier to obtain, especially for patients requiring regular refills.

Drivers

The rising prevalence of diabetes remains the key growth driver for the Insulin Biosimilars Market. Increasing obesity, sedentary lifestyles, aging populations, unhealthy diets, and urbanization are contributing to a larger diabetic population worldwide. Patients with Type 1 diabetes depend on insulin for survival, while many patients with Type 2 diabetes require insulin as the disease progresses. This creates continuous demand for safe, effective, and affordable insulin products.

High costs associated with branded insulin therapies have also accelerated interest in biosimilar alternatives. Many healthcare systems are under pressure to reduce pharmaceutical spending while maintaining treatment quality. Biosimilar insulin products can help lower costs for patients and payers, improving adherence and reducing the risk of treatment interruption. Patent expirations of established insulin products are further creating opportunities for biosimilar manufacturers to enter the market.

In addition, supportive regulatory pathways are encouraging product development and commercialization. Clearer approval standards, growing real-world experience, and increasing acceptance among clinicians are strengthening the market outlook. As more biosimilar insulin products become available, healthcare providers are expected to gain greater confidence in prescribing them for both new and existing patients.

Business Opportunity

The Insulin Biosimilars Market offers strong opportunities for pharmaceutical companies, biotechnology firms, contract manufacturers, and distribution partners. Companies that can provide high-quality insulin biosimilars at competitive prices are well positioned to benefit from growing demand. Long-acting insulin biosimilars are expected to offer notable opportunities due to their convenience in daily diabetes management, while rapid-acting insulin analogs are likely to gain traction among patients needing mealtime glucose control.

Partnerships between global pharmaceutical companies and regional manufacturers can help improve market penetration, especially in price-sensitive countries. Local production, efficient cold-chain distribution, and strong pharmacy networks will be critical for expanding access. Companies can also strengthen their position by offering patient support programs, education initiatives, and device-compatible insulin delivery formats such as pens and cartridges.

Digital healthcare platforms present another opportunity. Online pharmacies and telehealth-supported diabetes care can improve treatment continuity, refill management, and patient education. Manufacturers that combine affordability with reliable supply, strong clinical data, and post-market safety monitoring are expected to gain a competitive advantage.

Region Analysis

North America is a significant market for insulin biosimilars due to high diabetes prevalence, advanced healthcare infrastructure, and rising focus on insulin affordability. Payers, healthcare providers, and policymakers are increasingly exploring biosimilar options to reduce treatment costs and improve access. Regulatory support and growing competition are expected to further strengthen market adoption in the region.

Europe is also an important market, supported by established biosimilar acceptance, structured reimbursement systems, and physician familiarity with biologic alternatives. The region has been an early adopter of biosimilars across multiple therapeutic areas, creating a favorable environment for insulin biosimilar growth.

Asia Pacific is expected to create substantial growth opportunities due to its large diabetic population, expanding healthcare access, and increasing domestic biosimilar production. Countries in the region are focusing on improving chronic disease management and reducing dependence on expensive imported medicines. Latin America and the Middle East & Africa are also expected to witness gradual adoption as governments and healthcare providers seek affordable insulin options. Across all regions, growth will depend on regulatory confidence, pricing policies, physician education, and patient acceptance.

Key Players

The competitive landscape includes established insulin manufacturers, global pharmaceutical companies, biosimilar developers, and regional players focused on improving diabetes treatment access. Key players in the Insulin Biosimilars Market include:

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi S.A.
  • Biocon Biologics Ltd.
  • Viatris Inc.
  • Boehringer Ingelheim
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Gan & Lee Pharmaceuticals Co., Ltd.
  • Wockhardt Ltd.
  • Julphar Gulf Pharmaceutical Industries
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Ypsomed AG
  • Lannett Company, Inc.
  • Sandoz Group AG

Segmentation

By Type:

  • Fast-acting Insulin Rapid-acting Insulin Analogs Regular Human Insulin
  • Intermediate-acting Insulin NPH Human Insulin Pre-mixed Insulin
  • Long-acting Insulin

By Indication:

  • Diabetes Type 1
  • Diabetes Type 2

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Insulin Biosimilars Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Insulin Biosimilars Market Outlook, 2020 - 2033

  • 3.1. Global Insulin Biosimilars Market Outlook, by Type, Value (US$ Bn) & Volume (Units), 2020-2033
    • 3.1.1. Fast-acting Insulin
    • 3.1.2. Intermediate-acting Insulin
    • 3.1.3. Long-acting Insulin
  • 3.2. Global Insulin Biosimilars Market Outlook, by Indication, Value (US$ Bn) & Volume (Units), 2020-2033
    • 3.2.1. Diabetes Type 1
    • 3.2.2. Diabetes Type 2
  • 3.3. Global Insulin Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) & Volume (Units), 2020-2033
    • 3.3.1. Hospital Pharmacies
    • 3.3.2. Retail Pharmacies
    • 3.3.3. Drug Stores
    • 3.3.4. Online Pharmacies
  • 3.4. Global Insulin Biosimilars Market Outlook, by Region, Value (US$ Bn) & Volume (Units), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Insulin Biosimilars Market Outlook, 2020 - 2033

  • 4.1. North America Insulin Biosimilars Market Outlook, by Type, Value (US$ Bn) & Volume (Units), 2020-2033
    • 4.1.1. Fast-acting Insulin
    • 4.1.2. Intermediate-acting Insulin
    • 4.1.3. Long-acting Insulin
  • 4.2. North America Insulin Biosimilars Market Outlook, by Indication, Value (US$ Bn) & Volume (Units), 2020-2033
    • 4.2.1. Diabetes Type 1
    • 4.2.2. Diabetes Type 2
  • 4.3. North America Insulin Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) & Volume (Units), 2020-2033
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. Drug Stores
    • 4.3.4. Online Pharmacies
  • 4.4. North America Insulin Biosimilars Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033
    • 4.4.1. U.S. Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 4.4.2. U.S. Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 4.4.3. U.S. Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 4.4.4. Canada Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 4.4.5. Canada Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 4.4.6. Canada Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Insulin Biosimilars Market Outlook, 2020 - 2033

  • 5.1. Europe Insulin Biosimilars Market Outlook, by Type, Value (US$ Bn) & Volume (Units), 2020-2033
    • 5.1.1. Fast-acting Insulin
    • 5.1.2. Intermediate-acting Insulin
    • 5.1.3. Long-acting Insulin
  • 5.2. Europe Insulin Biosimilars Market Outlook, by Indication, Value (US$ Bn) & Volume (Units), 2020-2033
    • 5.2.1. Diabetes Type 1
    • 5.2.2. Diabetes Type 2
  • 5.3. Europe Insulin Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) & Volume (Units), 2020-2033
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Drug Stores
    • 5.3.4. Online Pharmacies
  • 5.4. Europe Insulin Biosimilars Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033
    • 5.4.1. Germany Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 5.4.2. Germany Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 5.4.3. Germany Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.4. Italy Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 5.4.5. Italy Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 5.4.6. Italy Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.7. France Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 5.4.8. France Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 5.4.9. France Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.10. U.K. Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 5.4.11. U.K. Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 5.4.12. U.K. Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.13. Spain Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 5.4.14. Spain Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 5.4.15. Spain Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.16. Russia Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 5.4.17. Russia Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 5.4.18. Russia Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.19. Rest of Europe Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 5.4.20. Rest of Europe Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 5.4.21. Rest of Europe Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Insulin Biosimilars Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Insulin Biosimilars Market Outlook, by Type, Value (US$ Bn) & Volume (Units), 2020-2033
    • 6.1.1. Fast-acting Insulin
    • 6.1.2. Intermediate-acting Insulin
    • 6.1.3. Long-acting Insulin
  • 6.2. Asia Pacific Insulin Biosimilars Market Outlook, by Indication, Value (US$ Bn) & Volume (Units), 2020-2033
    • 6.2.1. Diabetes Type 1
    • 6.2.2. Diabetes Type 2
  • 6.3. Asia Pacific Insulin Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) & Volume (Units), 2020-2033
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Drug Stores
    • 6.3.4. Online Pharmacies
  • 6.4. Asia Pacific Insulin Biosimilars Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033
    • 6.4.1. China Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 6.4.2. China Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 6.4.3. China Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.4. Japan Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 6.4.5. Japan Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 6.4.6. Japan Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.7. South Korea Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 6.4.8. South Korea Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 6.4.9. South Korea Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.10. India Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 6.4.11. India Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 6.4.12. India Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.13. Southeast Asia Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 6.4.14. Southeast Asia Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 6.4.15. Southeast Asia Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.16. Rest of SAO Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 6.4.17. Rest of SAO Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 6.4.18. Rest of SAO Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Insulin Biosimilars Market Outlook, 2020 - 2033

  • 7.1. Latin America Insulin Biosimilars Market Outlook, by Type, Value (US$ Bn) & Volume (Units), 2020-2033
    • 7.1.1. Fast-acting Insulin
    • 7.1.2. Intermediate-acting Insulin
    • 7.1.3. Long-acting Insulin
  • 7.2. Latin America Insulin Biosimilars Market Outlook, by Indication, Value (US$ Bn) & Volume (Units), 2020-2033
    • 7.2.1. Diabetes Type 1
    • 7.2.2. Diabetes Type 2
  • 7.3. Latin America Insulin Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) & Volume (Units), 2020-2033
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Drug Stores
    • 7.3.4. Online Pharmacies
  • 7.4. Latin America Insulin Biosimilars Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033
    • 7.4.1. Brazil Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 7.4.2. Brazil Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 7.4.3. Brazil Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.4. Mexico Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 7.4.5. Mexico Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 7.4.6. Mexico Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.7. Argentina Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 7.4.8. Argentina Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 7.4.9. Argentina Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.10. Rest of LATAM Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 7.4.11. Rest of LATAM Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 7.4.12. Rest of LATAM Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Insulin Biosimilars Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Insulin Biosimilars Market Outlook, by Type, Value (US$ Bn) & Volume (Units), 2020-2033
    • 8.1.1. Fast-acting Insulin
    • 8.1.2. Intermediate-acting Insulin
    • 8.1.3. Long-acting Insulin
  • 8.2. Middle East & Africa Insulin Biosimilars Market Outlook, by Indication, Value (US$ Bn) & Volume (Units), 2020-2033
    • 8.2.1. Diabetes Type 1
    • 8.2.2. Diabetes Type 2
  • 8.3. Middle East & Africa Insulin Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) & Volume (Units), 2020-2033
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Drug Stores
    • 8.3.4. Online Pharmacies
  • 8.4. Middle East & Africa Insulin Biosimilars Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033
    • 8.4.1. GCC Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 8.4.2. GCC Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 8.4.3. GCC Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.4. South Africa Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 8.4.5. South Africa Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 8.4.6. South Africa Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.7. Egypt Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 8.4.8. Egypt Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 8.4.9. Egypt Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.10. Nigeria Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 8.4.11. Nigeria Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 8.4.12. Nigeria Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.13. Rest of Middle East Insulin Biosimilars Market Outlook, by Type, 2020-2033
    • 8.4.14. Rest of Middle East Insulin Biosimilars Market Outlook, by Indication, 2020-2033
    • 8.4.15. Rest of Middle East Insulin Biosimilars Market Outlook, by Distribution Channel, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novo Nordisk A/S
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Eli Lilly and Company
    • 9.4.3. Sanofi S.A.
    • 9.4.4. Biocon Biologics Ltd.
    • 9.4.5. Viatris Inc.
    • 9.4.6. Boehringer Ingelheim
    • 9.4.7. Merck & Co., Inc.
    • 9.4.8. Pfizer Inc.
    • 9.4.9. Gan & Lee Pharmaceuticals Co., Ltd.
    • 9.4.10. Wockhardt Ltd.
    • 9.4.11. Julphar Gulf Pharmaceutical Industries
    • 9.4.12. Tonghua Dongbao Pharmaceutical Co., Ltd.
    • 9.4.13. Ypsomed AG
    • 9.4.14. Lannett Company, Inc.
    • 9.4.15. Sandoz Group AG

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations